Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma. Issue 24 (19th October 2021)

• Record Type: Journal Article
• Authors: Kong, Huimin; Ju, Enguo; Yi, Ke; Xu, Weiguo; Lao, Yeh‐Hsing; Cheng, Du; Zhang, Qi; Tao, Yu; Li, Mingqiang; Ding, Jianxun
• Is Part Of: Advanced science. Volume 8:Issue 24(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-10-19
• Subjects: CRISPR/Cas -- gene editing -- hepatocellular carcinoma -- nanotheranostics -- viral hepatitis; Science -- Periodicals; 505
• DOI: 10.1002/advs.202102051
• Languages: English
• ISSNs: 2198-3844

Abstract

Abstract: Liver disease, particularly viral hepatitis and hepatocellular carcinoma (HCC), is a global healthcare burden and leads to more than 2 million deaths per year worldwide. Despite some success in diagnosis and vaccine development, there are still unmet needs to improve diagnostics and therapeutics for viral hepatitis and HCC. The emerging clustered regularly interspaced short palindromic repeat/associated proteins (CRISPR/Cas) technology may open up a unique avenue to tackle these two diseases at the genetic level in a precise manner. Especially, liver is a more accessible organ over others from the delivery point of view, and many advanced strategies applied for nanotheranostics can be adapted in CRISPR‐mediated diagnostics or liver gene editing. In this review, the focus is on these two aspects of viral hepatitis and HCC applications. An overview on CRISPR editor development and current progress in clinical trials is first given, followed by highlighting the recent advances integrating the merits of gene editing and nanotheranostics. The promising systems that are used in other applications but may hold potentials in liver gene editing are also discussed. This review concludes with the perspectives on rationally designing the next‐generation CRISPR approaches and improving the editing performance. Abstract : Herein, the clustered regularly interspaced short palindromic repeat (CRISPR) nanotheranostics developed for viral hepatitis and hepatocellular carcinoma are reviewed, and rational design considerations for the next‐generation nanomedicine approaches to advance liver gene editing are discussed, highlighting their significances in clinical applications.